GLP-1 Weight Loss Drugs: Risk to Muscle Mass

A new American study warns that popular GLP-1 weight loss drugs may reduce muscle mass, raising concerns about long-term health.

Researchers at the University of Virginia (UVA) published a study in The Journal of Clinical Endocrinology & Metabolism, highlighting that while GLP-1 drugs aid in weight loss, they also significantly reduce muscle mass, potentially endangering cardiovascular health and overall well-being.

Zhenqi Liu, a professor of Medicine at the UVA School of Medicine, reported that patients described a feeling of muscle loss while taking these drugs. The study points out that up to 40% of weight loss can be attributed to the loss of fat-free mass, primarily muscle mass.

Researchers are concerned that the reduction in muscle mass may affect cardiorespiratory fitness (CRF), an indicator of cardiovascular health. Siddhartha Angadi, associate professor of Kinesiology at UVA, emphasized that CRF is a better predictor of mortality than weight.

The study suggests that patients taking GLP-1 should discuss strategies with their doctors to maintain muscle mass, such as exercise and adequate protein intake.

While research on muscle-preserving drugs is ongoing, experts emphasize the importance of monitoring and maintaining muscle mass during GLP-1 therapy.